Production of Genetically Engineered Golden Syrian Hamsters by Pronuclear Injection of the CRISPR/Cas9 Complex by Li, Rong et al.
TITLE: 
Production of Genetically Engineered Golden Syrian Hamsters by Pronuclear Injection of 
the CRISPR/Cas9 Complex 
 
AUTHORS: 
Rong Li1*, Jinxin Miao1,2*, Zhiqiang Fan1, SeokHwan Song3, Il-keun Kong3,4, Yaohe Wang2,5 
and Zhongde Wang1 
 
1Rong Li 
Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah, 
USA 
lirong14@gmail.com 
 
1,2Jinxin Miao 
1Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah, 
USA 
 
2National Centre for International Research in Cell and Gene Therapy, Sino-British Research 
Centre, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, P. R. China 
jinxin.miao@aggiemail.usu.edu 
 
1Zhiqiang Fan 
Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah, 
USA 
zhiqiangfan@hotmail.com 
 
3SeokHwan Song 
Department of Animal Science Division of Applied Life Science (BK21 Plus), Gyeongsang 
National University, Jinju 52828, Gyeongnam Province, Republic of Korea. 
siwd2002@gmail.com 
 
3,4Il-keun Kong 
3Department of Animal Science, Division of Applied Life Science (BK21 Plus)  
4Institute of Agriculture and Life Science, Gyeongsang National University, Jinju 52828, 
Gyeongnam Province, Republic of Korea. 
ikong7900@gmail.com 
 
2,5Yaohe Wang 
2National Centre for International Research in Cell and Gene Therapy, Sino-British Research 
Centre, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, P. R. China 
 
3Centre for Molecular Oncology, 
Barts Cancer Institute, 
Queen Mary University of London, London, UK 
yaohe.wang@qmul.ac.uk 
 
1Zhongde Wang 
Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah, 
USA 
zonda.wang@usu.edu 
 
CORRESPONDING AUTHOR:  
Zhongde Wang, Ph.D. Tel: 435-797-9668 
 
*These authors contributed equally to this work. 
 
KEYWORDS:  
Pronuclear injection, CRISPR/Cas9, gene editing, knockout, zygote, embryo transfer, animal 
model, golden Syrian hamster 
 
SHORT ABSTRACT: 
Pronuclear (PN) injection of the clustered regularly interspaced short palindromic repeats 
(CRISPR) and CRISPR-associated protein-9 nuclease (CRISPR/Cas9) system is a highly 
efficient method for producing genetically engineered golden Syrian hamsters. Herein, we 
describe the detailed PN injection protocol for the production of gene knockout hamsters with 
the CRISPR/Cas9 system. 
 
LONG ABSTRACT: 
The pronuclear (PN) injection technique was first established in mice to introduce foreign 
genetic materials into the pronuclei of one-cell stage embryos. The introduced genetic material 
may integrate into the embryonic genome and generate transgenic animals with foreign genetic 
information following transfer of the injected embryos to foster mothers. Following the success 
in mice, PN injection has been applied successfully in many other animal species. Recently, PN 
injection has been successfully employed to introduce reagents with gene-modifying activities, 
such as the CRISPR/Cas9 system, to achieve site-specific genetic modifications in several 
laboratory and farm animal species. In addition to mastering the special set of microinjection 
skills to produce genetically modified animals by PN injection, researchers must understand the 
reproduction physiology and behavior of the target species, because each species presents unique 
challenges. For example, golden Syrian hamster embryos have unique handling requirements in 
vitro such that PN injection techniques were not possible in this species until recent 
breakthroughs by our group. With our species-modified PN injection protocol, we have 
succeeded in producing several gene knockout (KO) and knockin (KI) hamsters, which have 
been used successfully to model human diseases. Here we describe the PN injection procedure 
for delivering the CRISPR/Cas9 complex to the zygotes of the hamster, the embryo handling 
conditions, embryo transfer procedures, and husbandry required to produce genetically modified 
hamsters. 
 
INTRODUCTION: 
The golden Syrian hamster (Mesocricetus auratus) is one of the most widely used rodents for 
biomedical research. According to the U.S. Department of Agriculture, approximately 100,000 
hamsters were used in the United States in 2015, representing 13% of total laboratory animal 
usage among the species covered by the Animal Welfare Act (http://www.aphis.usda.gov; 
accessed March 10, 2017). 
 
The hamster offers several advantages over other rodents in the study of a number of human 
diseases. For example, the histopathology of N-nitrosobis(2-oxopropyl)amine (BOP) induced 
pancreatic ductal adenocarcinomas in hamsters is similar to human pancreatic tumors, while 
BOP treatment mainly induces thyroid gland tumors in rats and lung and liver tumors in mice1. 
Because hamsters are the only small rodent found to support the replication of adenoviruses, they 
are also the model of choice for testing adenovirus-based oncolytic vectors and anti-adenovirus 
drugs2-4. Another example wherein the hamster model offers an advantage over mice and rats is 
in the study of hyperlipidemia. Humans and hamsters exhibit great similarities in lipid metabolic 
pathways and both species carry the gene encoding cholesteryl ester transfer protein (CETP), 
which plays a central role in lipid metabolisms, while CETP is absent in mice and rats5. 
Additionally, hamsters develop hemorrhagic disease more representative of the human 
manifestation following exposure to Ebola virus6. Hamsters are also the models of choice for 
studying atherosclerosis7, oral carcinomas8, and inflammatory myopathies9. Recently, it has also 
been demonstrated that hamsters are highly susceptible to Andes virus infection and develop 
hantavirus pulmonary syndrome-like disease, providing the only rodent model of Andes virus 
infection10. 
 
To address the unmet need for novel genetic animal models to study the human diseases where 
no reliable small rodent model is available, we recently have succeeded in applying the 
CRISPR/Cas9 system to the hamster and have produced several lines of genetically engineered 
hamsters11. Hamster zygotes are highly sensitive to environmental milieus such that the PN 
injection protocols developed in other species are unsuitable. Therefore, we developed a PN 
injection protocol for the hamster that accommodates the special requirements for handling 
hamster embryos in vitro. Here, we describe the detailed PN injection procedure using the 
CRISPR/Cas9 system and the accompanying steps, from the preparation of single guide RNA 
(sgRNA) to the transfer of injected embryos into recipient females. 
 
PROTOCOL: 
 
The procedures described in this protocol were approved by the Institutional Animal Care and 
Use Committee (IACUC) of Utah State University (IACUC protocol: 2484). Hamsters used in 
this protocol are adult (6-10 weeks of age) LVG strain golden Syrian hamsters. All hamsters are 
housed in the vivarium at the Bioinnovation center, Utah State University. Room temperature is 
set at 23 oC, humidity is set at 40-50%, and light cycle is set 14L:10D (light:dark).  
 
1. sgRNA and Cas9/sgRNA Ribonucleoproteins (RNP) Preparation 
1.1) Synthesize sgRNAs following the in vitro transcription procedures described in the 
manual of synthesis kit (Table 1, Supplement 1).  
 
1.2) To assemble ribonucleoproteins, mix 2 µg of Cas9 with 1 µg of sgRNA and incubate at 
room temperature for 10-15 min. For PN injection, make a working solution at the concentration 
of 100 ng/µL Cas9 and 50 ng/µL sgRNA with 10mM TE buffer (RNase free, Table 1). 
 
2. Vasectomy Preparation 
Note: Vasectomy is performed on male hamsters at 6-8 weeks of age. The surgery should be 
performed 10-14 days ahead of the first mating. Sterility is confirmed by failed pregnancies from 
mating with fertile females. Vasectomized males can normally be used for a year before they 
become less sexually active.  
 
2.1) Anesthetize males by intraperitoneal (i.p.) injection of ketamine/xylazine with a dose of 
40 mg/kg (ketamine) and 10 mg/kg (xylazine). Confirm anesthesia by lack of a pedal reflex (toe 
pinch). 
 
2.2) Lay the sedated hamster in dorsal recumbency on a dry tissue paper. Rinse the abdomen 
with three rounds of antiseptic treatments by alternating surgical scrub solutions between 70% 
alcohol and povidone-iodine. 
 
2.3) Make a vertical incision with surgical scissors starting 1.5 cm cranial to the prepuce 
extending 1 cm to each side from mid line (Figure 1a). Incise the skin, subcutaneous tissue, and 
linea alba to access the peritoneal space (Figure 1b).  
 
2.4) Apply gentle pressure to the caudal aspect of the scrotum to force the testes and fat tissue 
out. Grasp the vas deferens gently with forceps and carefully separate the blood vessel from the 
vas with a second set of forceps (Figure 1c). 
 
2.5) Hold the vas deferens with forceps to form a loop. Heat the tip of another forceps in 
flame until it is red, and then use it to remove the loop of the vas deferens. Insert fat tissue and 
testes back to abdomen. Remove the vas deferens on the opposing side with the same 
procedures. 
 
2.6) Suture the musculature first followed by suturing the skin. Place the animal on a warm 
pad in a cage for 30 min until the animal recovers. Observe the animal until it resumes normal 
activity. 
 
3. Donor/Recipient Hamster Preparation Schedule 
3.1) Monitor and record estrous cycles.  
 
Note: Female hamsters have a stable 4-days estrous cycle that is maintained immediately after 
parturition. Females on the first day of estrous can be identified by the opaque, yellowish and 
sticky vaginal discharge (Figure 2a). Females on Day 4 of estrous can be identified by the 
transparent, sticky mucus (Figure 2b).  
 
3.2) For superovulation of donor hamster, superovulate the sexually mature females (>6 
weeks) on the first day of the estrous cycle by IP injection of pregnant mare’s serum 
gonadotropin (PMSG; dissolved in PBS as 50 IU/mL) (Table 2) between 9-12 AM.  
 
Note: PMSG is for inducing superovulation but not for estrous cycle synchronization. 
 
3.3) 80-84 h after injection of PMSG (Day 4, 6-8 PM), place the females in cages with males 
for mating. As hamster matings do not result in copulation plugs, ensure successful matings by 
watching the matings. 
 
3.4) Prepare pseudopregnant females by mating sexually mature females on Day 4 of estrous  
with vasectomized males. The time schedule for preparing donor and recipient females are 
shown in Table 3.  
 
Note: True pregnant females can also be used as recipients, i.e., females with a coat color 
distinguishable from the golden color matted with the same color fertile males. Pups derived 
from embryo transfer can be identified based on coat colors. A potential advantage in using true 
pregnant females is that endogenously produced embryos would ensure successful pregnancies 
and help PN injected embryos to implant; a potential drawback in using true pregnant females as 
recipients is that PN injected embryos need to compete with endogenously produced embryos for 
implantation. 
 
4. Zygote Isolation 
4.1) Prepare culture medium (HECM-9; recipe is described in Supplement 2), as described 
previously in McKiernan and Bavister12. 
 
4.2) One day prior to PN injection, prepare zygote handling dishes (25 µL/drop) and a PN 
injection drop (100 µL) in the lid of a 35 mm dish with HECM-9. Then cover the medium drops 
with mineral oil. Balance medium in an incubator overnight under the following conditions: 37.5 
oC, 10% CO2, 5% O2, 85% N2 and 100% humidity. 
 
4.3) On the day scheduled for PN injection, prepare embryo flushing dishes (1 dish/donor 
hamster) with HECM-9 and store all dishes in the incubator until use. 
 
4.4) Euthanize superovulated hamsters with CO2. 
 
4.5) Oviduct Isolation 
 
4.5.1) Place a euthanized female hamster in dorsal recumbency on a surgical drape or tissue 
paper and prepare the abdomen with a 70% ethanol spray. 
 
4.5.2) Firmly hold skin and abdominal muscle layer at the midline and make an incision. Incise 
the peritoneum to expose the abdominal organs. 
 
4.5.3) Grasp one of the uterine horns with a fine forceps and retract the tissue from the 
abdomen. Separate the uterus from the mesometrium and fat tissue. Make a cut between the 
oviduct and ovary and a second cut adjacent to the junction of the oviduct and uterus (include a 
small part of uterus). Place the two oviducts  in the same flush dish. 
 
4.6) Flush and collect zygotes 
 
4.6.1) Under the dissection microscope, grasp the side of uterine horn with a #5 Dumont forceps 
and insert a homemade needle (Figure 3) into the lumen of the oviduct from the infundibular end 
and flush the oviduct with 300-400 µL of HECM-9 medium. 
 
4.6.2) Collect the zygotes immediately and wash them twice with HECM-9 medium in the 
handling dish. At this stage of development, all of the zygotes should be denuded from cumulus 
cells. 
 
4.6.3) Place the zygotes in an incubator (37.5 oC, 10% CO2, 5% O2, 85% N2 and 100% 
humidity) immediately after collection to minimize exposure to light . 
 
5. PN Injection 
5.1) Thaw the Cas9/sgRNA RNP on ice and maintain the complex on ice during the entire PN 
injection process. 
 
5.2) Load the injection needles with Cas9/sgRNA RNP solution immediately before the 
injection experiments. Place the rear end of the injection needles into the tube containing the 
Cas9/sgRNA RNP solution and allow the Cas9/sgRNA RNP solution to fill the needle by 
capillary action. 
 
5.3) Prepare the injection dish and needles. Fill the holder pipette with mineral oil to within 
~3mm of the bend of the holder needle. Place the holder in the microinjector with the tip of the 
needle horizontal to the bottom of the dish and fill the tip of the needle with medium by suction. 
Set the injection needle at a 10-15o angle opposite to holder. 
 
5.4) PN injection 
5.4.1) Identify a zygote and apply a fine suction with the holder needle. Ideally, the male and 
female pronuclei are within the same focal range and aligned parallel to holder. 
 
5.4.2) Penetrate the zona and male pronuclei (3 o’clock position) with the injection needle. 
 
5.4.3) Withdraw the injection needle quickly once the pronucleus swells to  prevent the nucleus 
from adhering to the needle and to avoid damaging the pronucleus. 
 
6. Zygotes Transfer to Pseudopregnant Hamsters 
6.1) Anesthetize a pseudopregnant hamster (the same way as described in the vasectomy 
section above) and lay it on a surgical drape or dry tissue paper in ventral recumbency.  
 
6.2) Cover the head with a cloth or paper to protect the eyes from light. Shave a proper skin 
area for incision on both sides. Prepare the lateral aspect of the body with 3 times of povidone-
iodine scrubs and 3 times  70% ethanol scrubs. Make a 2 cm vertical incision 2 cm caudal to the 
last rib (as shown in Figures 4a, 4b) on each side of the back of the animal. 
 
6.3) Grasp the fat pad with forceps and pull gently until the oviduct and uterus are visible. 
Clamp the fat pad with a hemostats and reflect the fat pad dorsally over the spine (Figure 4c). 
Position the reproductive tract such that the uterine tube can be penetrated with a 30 gauge 
needle for embryo transfer (Figure 4d). 
 
6.4) Wash the injected zygotes with HECM-9 in a new dish. Use a new glass pipette 
(diameter: ~150-200 µm) to load 10-15 zygotes. Arrange the zygotes as a chain of pearls 
followed by several air bubbles. Insert the pipette into the open penetrated tube from step 6.3 and 
gently blow into the pipette to transfer the zygotes to the oviduct. Continue blowing until the first 
air bubble is released into the oviduct tract (Figure 4e). 
 
6.5) Release the fat pad and return the tissue to the abdomen. Transfer approximately the 
same number (10-15) of injected embryos to another oviduct tract by the same processes. 
 
6.6) Suture the musculature and the skin in 2 layers. Return the hamster to a cage and place 
the cage on a warm pad for recovery. Return the cage to the animal room when the animal fully 
recovered from anesthesia. 
 
REPRESENTATIVE RESULTS: 
The efficiency of the described protocol in producing genetically modified hamsters depends on 
the outcomes of the following two critical steps: the live birth rate of recipient females and the 
number of live pups with the intended genetic modifications. The live birth rate is a direct results 
of the embryo quality and the skill of the individual performing the PN injection and embryo 
transfer procedures. To ensure that the developmental potential of manipulated embryos is not 
compromised, great care is necessary during the in vitro handling of the hamster embryos. We 
regularly achieve a live birth rate of 60-80% with pseudopregnant recipient females. Table 4 
illustrates live birth rates from the RAG1 knockout experiment (pseudopregnant females were 
used) and the STAT2 knockout experiment (true pregnant black females were used; live birth rate 
in this case was calculated as the percentage of litters produced golden pups).  
 
The percentage of genetically modified pups produced from PN injected embryos depends on 
both the efficiency of sgRNA in introducing indels and the successful injection of the 
Cas9/sgRNA ribonucleoproteins into the pronuclei. We found that sgRNA efficiency varies 
among gene targets (unpublished observations). As shown in Table 4, the sgRNA designed for 
STAT2 resulted in a gene targeting efficiency of 88.9%, while the sgRNA for RAG1 was only 
28.6% efficient. Figure 5 provides an example of the genotyping results from a PCR restriction 
fragment length polymorphism (PCR-RFLP) assay of pups from RAG1 gene targeting. It is 
important to note that some indels may occur outside of the restriction enzyme recognition 
sequence, such that PCR-RFLP may underestimate the gene targeting efficiency. Subcloning the 
PCR products into TA cloning vectors followed by Sanger sequencing of the PCR inserts are 
necessary to accurately measure gene targeting efficiency and to reveal the nature of indels.  
 
Figure 1: Male hamster vasectomy.  
a) and b) Make a 2 cm vertical incision beginning 1.5 cm cranial to the prepuce extending 
cranially; c) Separate the vas deference from the associated testicular vein and artery with two 
pairs of forceps; d) Grasp the vas deferens with a forceps to form a 1 cm loop. Heat a second set 
of forceps and excise the loop while cauterizing the ends concurrently.  
 
Figure 2: Estrous cycle.  
a) The vaginal discharge observed on Day 1 is opaque, yellowish, and sticky b) The vaginal 
discharge observable on Day 4 is clear and sticky. 
 
Figure 3: Preparation of the needle for embryo isolation.  
a) Fracture a 30 gauge needle along the red line and polish the tip until it is flat and smooth. b) 
make a 30-40o angle at ~3 mm from the tip. 
 
Figure 4: Zygote transfer.  
a) and b) Make a 2 cm long vertical incision starting 2 cm caudal to the last rib (red line); c) 
Clamp the fat pad with a Hemostats and reflect the tissue dorsally; d) Adjust the position of 
oviduct tract and penetrate an open with a 30 gauge needle; e) Arrange the zygotes as a chain of 
pearls within the embryo transfer glass pipette and transfer them into the  oviduct from the 
penetrated open. Bar=1000 µm. 
 
Figure 5. PCR-RFLP assay of a single litter of  founder animals with RAG1 indels. M: 1 Kb Plus 
ladder. WT: wild type. ID 1, 3 and 7 show uncut band consistent with RAG1 indels. 
 
DISCUSSION: 
To better exploit the potential of golden Syrian hamsters as models of human disease, we 
developed a PN injection protocol for delivering a CRISPR/Cas9 complex to target the hamster 
genome. The PN injection protocol optimizes several key variables including the embryo culture 
medium, temperature, and wavelengths of light13. There are also several hamster-specific animal 
handling procedures that need to follow for successfully conducting gene targeting in the 
hamster. For example, sexually matured female hamsters have stable 4-day estrous cycles that 
cannot be synchronized with exogenous hormones (e.g. PMSG). Thus accurately tracking the 
estrous cycles of each female is important for both superovulation and pseudopregnancy 
preparation. 30-60 zygotes can be produced from a female if she is successfully superovulated. 
To achieve successful superovulation, it is necessary to consider species-specific deposition of 
fat. Female hamsters, especially those over 12 weeks of age, tend to have excessive abdominal 
fat such that the syringe needle must be positioned correctly to fully penetrate the fat pad when 
performing hormone injections. We have found that penetration half-way into the peritoneal 
cavity achieves the appropriate distance for hormone delivery. We summarized the unique 
requirements for PN injection, hamster handling and husbandry in Table 5. 
 
For PN injection, the number of embryos transferred to the injection dish for each round of 
injection must be determined experimentally to avoid extended injection time. The longer the 
time the embryos remain in the dish, the greater the chance that they experience overexposure to 
light. We recommend transferring approximately 15 embryos to the injection dish for each round 
of injections. This number achieves a good balance between the number of rounds of injections 
and the tolerable exposure of the embryos to light. As both of the cytoplasmic and pronuclear 
membranes of hamster embryos are quite flexible, substantial force must be applied to the 
injection needle to penetrate the membrane of the pronucleus. During this time, the pronuclei 
must remain within the focal range.  
 
Researchers should consider the following surgical issues when performing embryo transfers. 
First, it is important that the incisions through the body wall correspond to the body size of the 
animal. If the incision is too small, it may result in extrusion of the zygotes from oviduct when 
returning the reproductive tract to the abdomen. In addition to incision size, the potential for 
extrusion of zygotes from the oviduct can be minimized by handling the associated fat pad rather 
than the reproductive tissue proper. In regard to incision size, it is also important to consider that  
larger incisions may cause more stress to the animal and exhibit a higher probability of 
complications (e.g. infection dehiscence). Second, to minimize bleeding, researchers should take 
care to avoid incising major blood vessels when accessing the abdomen because excess blood 
loss can  increase surgery stress to reduce the success of embryo transfer, and extend the 
recovery time.  
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Table 1. Key materials/equipments used in the protocol 
Materials/Equipments Company 
Catalog 
number Comments/Description 
Cas9 Invitrogen B25640 1 ug/ul (~6.1 uM) 
GeneArtTM Precision Synthesis Kit Invitrogen A29377 For sgRNA synthesis 
Albumin from human serum Sigma A1653 For cultivation medium 
Illuminator Nikon NI-150 For embryo transfer 
Incubator 
New 
Brunswick Galaxy 14S For embryo cultivation 
Microforge Narishige PB-7 
For making injection 
needles 
Microscope Nikon ECLIPSE Ti-S For microinjection 
Microscope invitrogen SMZ745T For embryo transfer 
Mineral oil Sigma M1840 Keep in dark 
PMSG Sigma G4877-2000IU For superovulation 
 
  
Table 2. PMSG does corresponding to body 
weights 
Body weight (g) PMSG (IU) PMSG (ul) 
<110 10 200 
110-135 15 300 
135-160 20 400 
160-185 25 500 
>185 30 600 
PMSG, pregnant mare’s serum gonadatropin 
  
Table 3. Time schedule of donor/recipient preparation 
Hamster Day 1 Day 2 Day 3 Day 4 Day 5 
Donor 
PMSG (9-12 
am)     
Mating (6-8 
pm) 
Zygote isolation (12-1 
pm) 
          PN injection (1-3 pm) 
Recipient       
Mating (6-8 
pm) Embryo transfer (3-5 pm) 
  
Table 4. Efficiency of gene targeting in golden Syrian hamster by the Cas9/sgRNA 
system 
Genes No. Embryos (Pups) No. Litters (Recipients) 
No. Positive pups 
(%) 
STAT2 229 (54) 14 (19)* 48 (88.9) 
RAG1 77 (21) 3 (3) 6 (28.6) 
* females matted with fertile males were used; the number of litters indicated is only those 
produced golden pups. 
  
Table 5. Unique requirements on hamster embryo handling and husbandry 
Condition/Handling Requirements Comments 
Ambient light Turn off all ambient light 
Hamster embryos are 
sensitive to light, especially 
to cool light 
Light during in vitro 
handling Less than 20 min for PN injection 
Manipulate 15 embryos per 
round to reduce light 
exposure 
Temperature Ambient temperature: 28±0.5 oC 
Hamster embryos are 
sensitive to temperature 
fluctuations Handling temperature: 37.5 oC 
Medium HECM-9 
Do not store more than 3 
days 
Culture condition 
37.5 oC, 10% CO2, 5% O2 and 
100% humidity 
Balanced overnight in 
incubator 
Husbandry after embryo 
transfer 
Don’t change cage within 5 days 
before/after due date 
Recipient will cannibalize 
pups if disturbed; provide 
enough feed/water  
  
  
Supplementary 1 
Synthesize sgRNA by GeneArt Precision Synthesis Kit 
1. Design and synthesize a pair of target forward (F) and reverse (R) primers based on the USER 
GUIDE.  
2. Prepare a 0.3 μM target oligonucleotide mix working solution in nuclease-free water.  
3. Set up the PCR assembly reaction:  
     Phusion High-Fidelity PCR Master Mix (2X)         12.5 μL  
     Tracr Fragment + T7 Primer Mix                            1 μL  
     0.3 μM Target F/R oligonucleotide mix            1 μL  
     Nuclease-free water                                                 10.5 μL  
4. Perform assembly PCR using the cycling parameters below.   
  Cycle step                                
 
Temperature Time  Cycles 
Initial denaturation 98°C 10 seconds 1X 
Denaturation 98°C 5 seconds 32X 
Annealing 55°C 15 seconds 
Final extension 72°C 1 minute 1X 
Hold  4°C Hold* 1X 
   
Perform in vitro transcription 
5. Set up the following in vitro transcription reaction, adding the reaction components in the order given.   
          NTP mix (100 mM each of ATP, GTP, CTP, UTP)             8 μL  
          gRNA DNA template (from PCR assembly, page 13)      6 μL  
          5X TranscriptAid™ Reaction Buffer                                    4 μL  
          TranscriptAid  Enzyme Mix                                                  2 μL   
6. Incubate at 37°C for 2–3 hours.  
7. Add 1 μL of DNase I into the reaction mix after the transcription reaction and incubate at 37°C for 15 
minutes. 
Purify in vitro transcribed (IVT) gRNA 
8. Adjust the volume of the IVT reaction to 200 μL with nuclease-free water.  
9. Add 100 μL of Binding Buffer. Mix thoroughly by pipetting.  
10. Add 300 μL of ethanol (>96%) and mix by pipetting.  
11. Transfer the mixture to the GeneJET  RNA Purification Micro Column and centrifuge for 30–60 
seconds at 14,000 × g. Discard the flow-through.  
12. Add 700 μL Wash Buffer 1(diluted with 13 mL of >96% ethanol) and centrifuge for 30–60 seconds at 
14,000 × g. Discard the flow-through.  
13. Add 700 μL Wash Buffer 2 (diluted with 30 mL of >96% ethanol) centrifuge for 30–60 seconds at 
14,000 × g. Discard the flow-through and repeat.  
14. Centrifuge the empty purification column for an additional 60 seconds at 14,000 × g to completely 
remove any residual Wash Buffer and transfer the purification column to a clean 1.5-mL collection 
tube.  
15. Add 10 μL of nuclease-free water to the center of the purification column filter, and centrifuge for 60 
seconds at 14,000 × g to elute the gRNA. 
  
Supplementary 2 
Hamster Embryo culture Medium-9 (HECM-9) recipe 
Components mMol/L 
Human Serum Albumin 
(HAS) 
0.5mg/ml 
NaCl 113.6 
KCl 3.0 
CaCl2 1.9 
MgCl2 0.5 
NaHCO3 25.0 
DL-Na-lactate 4.5 
HCL 1mol/L 1.4 μl/ml 
Taurine 0.50  
Asparagine 0.01  
Cysteine 0.01  
Histidine 0.01  
Lysine 0.01  
Proline 0.01  
Serine 0.01  
Aspartic acid 0.01  
Glycine 0.01  
Glutamic acid 0.01  
Glutamine 0.20 
Pantothenate 0.003 
 
Note: Inorganic salt solutions are prepared by dissolving the salts in Milli-Q water and can be 
kept at 4 oC for up to 3 days. Amino acids, vitamins and HSA are prepared as x100 stocks and 
are stored at -20 oC. HECM-9 is prepared by adding the stock solutions of amino acids, vitamins 
and HSA. HECM-9 should not be stored more than 3 days. The medium should be balanced in 
an atmosphere of 37 oC, 10% CO2, 5% O2, 85% N2 overnight before use. 
 
